Pharmacoeconomics MCQ
Q1. Full form of CMA
A. Cost-minimization analysis
B. Cost-morbidity analysis
C. Cost-mortality analysis
D. Cost-moles analysis
Correct Answer: (A) Cost-minimization analysis
Q2. What is an example of a CUA
A. When the program affects both morbidity and mortality and it is desirable to have a common unit of outcome
B. Total costs divided by amount of output
C. When the program has a wide range of outcomes
D. 10 year study to look at anti-diabetic drugs
Correct Answer: (D) 10 year study to look at anti-diabetic drugs
Q3. CUA is measured in terms of
A. Lost earnings due to death
B. Quantity and quality of life (QALY)
C. Choose the least costly alternative
D. When quality of life is the most important
Correct Answer: (B) Quantity and quality of life (QALY)
Q4. Full form of CUA
A. Cost-urban analysis
B. Complexity -utility analysis
C. Complexity-utilization analysis
D. Cost-utility analysis
Correct Answer: (D) Cost-utility analysis
Q5. Full form of CBA
A. Cost-beverages analysis
B. Cost-beneficiary analysis
C. Cost-benefit analysis
D. Cost-balanced diet analysis
Correct Answer: (C) Cost-benefit analysis
Q6. Full form of CEA
A. Cost-efficiency analysis
B. Cost-effectiveness analysis
C. Cost-efforts analysis
D. Cost coal-eastern analysis
Correct Answer: (B) Cost-effectiveness analysis
Q7. Mortality
A. Disability-adjusted life years
B. Quantity and quality of life (QALY)
C. Costs associated with changes in life expectancy (i.e., premature death)
D. Lost earnings due to death
Correct Answer: (D) Lost earnings due to death
Q8. Stakeholders involved in Pharmaco-economics
A. Pharmaceutical Manufacturers
B. Healthcare practitioners/prescriber
C. Pharmacists
D. All of the above
Correct Answer: (D) All of the above
Q9. Intangible cost
A. Costs associated with non-financial outcomes of disease and medical care (such as quality of life), which cannot be properly expressed in monetary terms
B. Total costs divided by amount of output
C. Additional cost of producing a given increment of effect (greater than 1)
D. All of the above
Correct Answer: (A) Costs associated with non-financial outcomes of disease and medical care (such as quality of life), which cannot be properly expressed in monetary terms
Q10. CUA’s are reported
A. Willing to pay
B. Opportunity cost
C. QALY & DALY
D. Non- financial
Correct Answer: (C) QALY & DALY
Q11. Morbidity cost equation
A. Chronic diseases
B. The extra costs required to produce one additional unit of effect
C. Morbidity cost = wage rate x lost days
D. Condition resulting from the ailments associated with a disease
Correct Answer: (C) Morbidity cost = wage rate x lost days
Q12. Pharmacoeconomics is
A. The study of the part of the U.S. economy devoted to drug use
B. The study of the impact of prescription drug costs on the overall economy
C. The analysis of the costs and consequences of any health care-related treatment or service
D. The analysis of the clinical efficacy of the drug
Correct Answer: (D) The analysis of the clinical efficacy of the drug
Q13. Intangible costs are measured by
A. Non-financial
B. Willingness to pay
C. QALY and DALY
D. Opportunity cost
Correct Answer: (A) Non-financial
Q14. Full form of ICER
A. International cost effectiveness ratio
B. India cost effectiveness ratio
C. Industrial cost effectiveness ratio
D. Incremental cost effectiveness ratio
Correct Answer: (D) Incremental cost effectiveness ratio
Q15. DALY stands for
A. Lost earnings due to death
B. When quality of life is the most important outcome
C. Quantity and quality of life
D. Disability-adjusted life years
Correct Answer: (D) Disability-adjusted life years
Q16. Costing
A. An economic analysis that assesses whether the outcome (benefits) outweighs the inputs (costs) of a program or intervention
B. This analysis is a tool to identify, examine, and compare the relevant costs and consequences of competing drug regimens and interventions
C. This analysis is used to identify and set priorities for policies
D. The process of identifying the costs of a disease and/or its associated treatment, and of breaking them down, and relating them to the various aspects of the disease and treatment
Correct Answer: (D) The process of identifying the costs of a disease and/or its associated treatment, and of breaking them down, and relating them to the various aspects of the disease and treatment
Q17. CEA Alternatives must have clear clinical outcome parameter
A. Three
B. One
C. Four
D. Five
Correct Answer: (B) One
Q18. Mortality costs are associated with losses in year’s of______ life
A. Morbidity cost = wage x lost days
B. Psychosocial cost
C. Productive
D. Natural units
Correct Answer: (C) Productive
Q19. Opportunity cost calculation
A. Lost earnings due to disability
B. Cost = total time x wage rate
C. Morbidity cost = wage rate x lost days
D. Total costs divided by amount of output
Correct Answer: (B) Cost = total time x wage rate
Q20. Cost-effectiveness analysis
A. This analysis is a tool to identify, examine, and compare the relevant costs and consequences of competing drug regimens and interventions
B. An economic analysis that assesses whether the outcome (benefits) outweighs the inputs (costs) of a program or Intervention
C. This analysis provides baseline information for other analyses
D. When quality of life is the most important
Correct Answer: (A) This analysis is a tool to identify, examine, and compare the relevant costs and consequences of competing drug regimens and interventions
Q21. Marginal cost
A. The value of the best-forgone option or the next best option, not necessarily the amount of money that change hands
B. Additional cost of producing a given increment of effect (greater than 1)
C. Condition resulting from the ailments associated with a disease
D. The extra costs required to produce one additional unit of effect
Correct Answer: (D) The extra costs required to produce one additional unit of effect
Q22. Terminologies of pharmaco-economics
A. Cost-minimization analysis
B. Cost-benefit analysis
C. Cost-effectiveness analysis
D. All of these
Correct Answer: (D) All of these
Q23. CBA
A. Consequences must shown to be equivalent or assumed to be equivalent
B. This analysis, both the units being measured must be expressed in monetary terms
C. Incremental cost-effectiveness ratio
D. This analysis provides baseline information for other analyses
Correct Answer: (B) This analysis, both the units being measured must be expressed in monetary terms
Q24. Cost of illness provides indications of whether or not resources are being utilized effectively
A. True
B. False
C. Neither True Nor False
D. None of the above
Correct Answer: (B) False